226 related articles for article (PubMed ID: 34168003)
21. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.
Potluri R; Ranjan S; Bhandari H; Johnson H; Moshyk A; Kotapati S
Exp Hematol Oncol; 2019; 8():14. PubMed ID: 31312536
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
24. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
Awada G; Ben Salama L; De Cremer J; Schwarze JK; Fischbuch L; Seynaeve L; Du Four S; Vanbinst AM; Michotte A; Everaert H; Rogiers A; Theuns P; Duerinck J; Neyns B
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067319
[TBL] [Abstract][Full Text] [Related]
25. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
27. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.
Mori T; Namikawa K; Yamazaki N; Kiniwa Y; Yamasaki O; Yoshikawa S; Inozume T; Kato H; Nakai Y; Fukushima S; Takenouchi T; Maekawa T; Matsushita S; Otsuka A; Nomura M; Baba N; Isei T; Saito S; Fujimoto N; Tanaka R; Kaneko T; Kuwatsuka Y; Matsuya T; Nagase K; Onishi M; Onuma T; Nakamura Y
Front Med (Lausanne); 2023; 10():1229937. PubMed ID: 37636577
[TBL] [Abstract][Full Text] [Related]
29. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kabu K; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 May; 51(6):966-975. PubMed ID: 33594427
[TBL] [Abstract][Full Text] [Related]
31. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
Reichert C; Baldini C; Mezghani S; Maubec E; Longvert C; Mortier L; Quereux G; Jannic A; Machet L; de Quatrebarbes J; Nardin C; Beneton N; Amini Adle M; Funck-Brentano E; Descamps V; Hachon L; Malissen N; Baroudjian B; Brunet-Possenti F;
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686606
[TBL] [Abstract][Full Text] [Related]
32. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454
[TBL] [Abstract][Full Text] [Related]
33. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C; Chaput-Gras N; Lanoy E; Larive A; Mateus C; Routier E; Sun R; Tao YG; Massard C; Bahleda R; Schwob D; Ibrahim N; Khoury Abboud RM; Caramella C; Lancia A; Cassard L; Roy S; Soria JC; Robert C; Deutsch E
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819972
[TBL] [Abstract][Full Text] [Related]
34. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab plus ipilimumab in advanced melanoma.
Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
[TBL] [Abstract][Full Text] [Related]
36. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
37. NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Sloan AE; Winter K; Gilbert MR; Aldape K; Choi S; Wen PY; Butowski N; Iwamoto FM; Raval RR; Voloschin AD; Kamiya-Matsuoka C; Won M; Mehta MP
Neuro Oncol; 2024 Jun; ():. PubMed ID: 38874333
[TBL] [Abstract][Full Text] [Related]
38. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Joseph RW; Liu FX; Shillington AC; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Saretsky TL; Pickard AS
Qual Life Res; 2020 Oct; 29(10):2651-2660. PubMed ID: 32405921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]